



Extension Seminar in Mental Health

Program

This seminar will be delivered by a combination of a 6-week self-paced learning package followed by a live one-day seminar

Self-paced learning package
available from Friday 15 March

Presentation	Learning objectives
Early intervention/First Episode psychosis	<ul style="list-style-type: none"> • Explain difficulties associated with first episode of psychosis diagnosis of schizophrenia • Identify treatment goals in consumers diagnosed with psychosis. • Explain principles of appropriate use of antipsychotics in young consumers • Describe issues unique to late onset psychosis
Recovery in psychosis	<ul style="list-style-type: none"> • Explain the general progression of chronic psychosis • Identify barriers to recovery. • Identify key members of the treatment team
Resistant schizophrenia	<ul style="list-style-type: none"> • Differentiate between treatment-resistant and other forms of schizophrenia • Describe challenges in diagnosing treatment-resistant schizophrenia • Explain the importance of a multidisciplinary care approach to the management of treatment-resistance schizophrenia
Psychopharmacology in psychosis	<ul style="list-style-type: none"> • Identify the roles of psychotropics in emergency sedation • Explain the indication for antipsychotic medications in the acute and recovery phases. • Assess the use and limitations of antipsychotics in treatment of psychosis • Compare the use medications for psychosis treatment and management in different sub-groups of consumers
Mental state examination	<ul style="list-style-type: none"> • Identify the domains within a mental state exam. • Explain the role of the mental state examination in diagnosis formulation. • Use the mental state exam information to identify signs and symptoms of apparent mental illness and associated risk factors.
Use of pathology and therapeutic drug monitoring	<ul style="list-style-type: none"> • Identify key pathological factors that impact medication metabolism and therapeutic outcomes in mental health therapeutics • Outline commonly monitored psychiatric medications and their therapeutic ranges • Explain how to interpret therapeutic drug monitoring (TDM) data for psychiatric medications • Explain how pathology insights and TDM can be integrated in the pharmacy practice
Consultation Liaison	<ul style="list-style-type: none"> • Define the role of Consultation Liaison Psychiatry services



	<ul style="list-style-type: none">• Overview the collaborative nature of CLP with multidisciplinary staff in optimising patient care
Communicating with consumer	<ul style="list-style-type: none">• Explain common barriers to communicating with consumers• Apply different approaches of communicating to meet individual consumer needs.
Overdose complications and risk mitigation	<ul style="list-style-type: none">• Identify high risk medications used in mental health care settings• Identify medication considerations when changing or recommencing therapies• Explain risk mitigation strategies for these considerations
Drug and alcohol withdrawal and treatment	<ul style="list-style-type: none">• Describe common signs and symptoms of alcohol, cannabis, opioid and psychostimulant withdrawal.• Identify risks associated with withdrawal.• Differentiate between withdrawal signs and symptoms and acute mental health disorders.• Apply common patterns of withdrawal to pharmacological needs of the consumer.
Drug and alcohol relapse prevention	<ul style="list-style-type: none">• Apply concepts of motivational interviewing within the inpatient setting.• Outline the role of pharmacological treatments within the overall treatment of drug and alcohol disorders.



Extension Seminar in Mental Health

Program

All times listed are in AEST

Live virtual seminar: Saturday 27 April 2024

Time (AEST)	Session
0920-0930	Online login available
0930-0940	Welcome, introduction, housekeeping
0940-1025	Review of self-paced learning package content with open Q&A Belinda Barrett , Clinical Pharmacist, Wagga Wagga Base Hospital Mental Health Unit, Wagga Wagga, NSW
1025-1130	Antipsychotics: When to switch and how Belinda Barrett , Clinical Pharmacist, Wagga Wagga Base Hospital Mental Health Unit, Wagga Wagga, NSW
1130-1150	Break
1150-1200	Case session 1 introduction: Complex case Jessie Chen , Senior Mental Health Pharmacist, Hornsby Hospital, Sydney, NSW
1200-1345	Case session 1: Multiple medications, overdose risk Tutors: Belinda Barrett, Nathan Chahoud, Sarah An, Jessie Chen, Yvette Haselden
1345-1415	Break
1415-1445	Working with mental health consumers Nathan Chahoud , Clinical Pharmacist, Orange Health Service, Orange, NSW
1445-1455	Case session 2 introduction Amy Sieff , Senior Pharmacist Medication Safety and Quality Use of Medicines, South Western Sydney Local Health District, Mental Health Services, Sydney, Qld
1455-1615	Case session 2: Collaboration with consumers for better health outcomes Tutors: Belinda Barrett, Nathan Chahoud, Amy Sieff, Sarah An, Yvette Haselden
1615-1630	Break
1630-1640	Case session 3 introduction Sarah An , Mental Health Pharmacist/Clozapine Coordinator, Royal Prince Alfred Hospital; Professor Marie Bashir Centre (Mental Health Facility), Camperdown, Vic
1630-1730	Case session 3: Substance misuse and management Tutors: Belinda Barrett, Nathan Chahoud, Amy Sieff, Sarah An, Yvette Haselden
1730-1745	Open Q&A
1745	Close of live virtual seminar

Please note: presentation recordings from the live virtual seminar will not be available.